Immunotherapy draws the lion's share of attention from top VCs, but startups focused on other types of cancer therapies, such as protein targeting, are also starting to gain recognition.
Immunotherapy draws the lion's share of attention from top VCs, but startups focused on other types of cancer therapies, such as protein targeting, are also starting to gain recognition.